You are here
Efficacy and Safety for Diabetes Specialists
The purpose of this course is to learn how the efficacy and safety of basal insulin–glucagon-like peptide-1 (GLP-1) receptor agonist combination therapy surpasses that of the individual components. Participants will learn how to identify patients who are most likely to benefit from this combination. Practical considerations will be discussed, including tips on how to best manage patients during treatment with basal insulin–GLP-1 receptor agonist combination therapy.
- Intensified treatment goals/options
- Data from phase 3 clinical trials
- Convenience of a single injection
This hallway conversation discusses the safety profile of basal insulin–GLP-1 RA combination therapy. The side-effects of the individual compounds (insulin and GLP-1 RAs) are discussed and compared with the side-effects of combination therapy. The discussion ends with a focus on patient experiences with basal insulin–GLP-1 RA combination therapy.
Please remember the following points while taking this assessment:
- The assessment consists of 10 questions
- You need to score a minimum of 80% to pass the assessment
- Read the question carefully, select an option provided below the question, and then click the “Submit” button
- You cannot change the answer once you have clicked the “Submit” button
- If you exit the assessment before completing all the questions, you will have to attempt it again from the beginning.
If you are planning to participate in one of our UEMS accredited courses and you want your name to show on the certificate, please update your profile with your title, first name and last name. To update your profile please go to "My profile", "Edit profile", click on "User profile" and "Edit profile header".
>> Click Start when you are ready to take the assessment
The aim of this evaluation process is to maintain high educational standards and provide a reference for continuous improvement.
Validity of accreditation: 2 years after date of accreditation by: UEMS-EACCME